Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors

被引：94

作者：

Ghatalia, Pooja ^{[1
]}

Morgan, Charity J. ^{[2
]}

Je, Youjin ^{[3
]}

Nguyen, Paul L. ^{[4
,5
]}

Quoc-Dien Trinh ^{[4
,5
]}

Choueiri, Toni K. ^{[4
,5
]}

Sonpavde, Guru ^{[6
]}

机构：

[1] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL USA

[2] Kyung Hee Univ, UAB Sch Publ Hlth, Dept Biostat, Seoul, South Korea

[3] Kyung Hee Univ, Dept Food & Nutr, Seoul, South Korea

[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Boston, MA USA

[6] UAB Med Ctr, Sect Med Oncol, Dept Internal Med, Birmingham, AL 35233 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2015年 / 94卷 / 02期

关键词：

Vascular endothelial growth factor receptor; Tyrosine kinase inhibitors; Approved; Congestive heart failure; Meta-analysis; PHASE-III TRIAL; DOUBLE-BLIND; 1ST-LINE TREATMENT; CANCER-PATIENTS; SUNITINIB; METAANALYSIS; PLACEBO; SORAFENIB; RISK; PLUS;

D O I：

10.1016/j.critrevonc.2014.12.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A systematic review and meta-analysis was conducted to determine the relative risk (RR) of congestive heart failure (CHIP) associated with approved multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized trials comparing arms with and without an FDA-approved VEGFR TKI. Statistical analyses calculated the relative risk (RR) and 95% confidence intervals (CI). A total of 10,647 patients from 16 phase III trials and 5 phase II trials were selected. All grade CHIP occurred in 138 of 5752 (2.39%) patients receiving VEGFR TKIs and 37 of 4895 (0.75%) patients in the non-TKI group. High-grade CHF occurred in 17 of 1426(1.19%) patients receiving VEGFR TKIs and 8 of 1232(0.65%) patients in the non-TKI group. The RR of all grade and high-grade CHF for the TKI vs. no TKI arms was 2.69 (p<0.001; 95% CI: 1.86 to 3.87) and 1.65 (p=0.227, 95% CI: 0.73 to 3.70), respectively. The RR of relatively specific TKIs (axitinib) was similar to relatively non-specific TKIs (sunitinib, sorafenib, vandetanib, pazopanib). (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：228 / 237

页数：10

共 39 条

[1] Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial [J].

Abou-Alfa, Ghassan K. ;

Johnson, Philip ;

Knox, Jennifer J. ;

Capanu, Marinela ;

Davidenko, Irina ;

Lacava, Juan ;

Leung, Thomas ;

Gansukh, Bolorsukh ;

Saltz, Leonard B. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (19) :2154-2160

[2]

[Anonymous], R PACKAGE VERSION 2

[3]

[Anonymous], NEW ENGL J MED

[4] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer [J].

Barrios, Carlos H. ;

Liu, Mei-Ching ;

Lee, Soo Chin ;

Vanlemmens, Laurence ;

Ferrero, Jean-Marc ;

Tabei, Toshio ;

Pivot, Xavier ;

Iwata, Hiroji ;

Aogi, Kenjiro ;

Lugo-Quintana, Roberto ;

Harbeck, Nadia ;

Brickman, Marla J. ;

Zhang, Ke ;

Kern, Kenneth A. ;

Martin, Miguel .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) :121-131

[5] First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study [J].

Bergh, Jonas ;

Bondarenko, Igor M. ;

Lichinitser, Mikhail R. ;

Liljegren, Annelie ;

Greil, Richard ;

Voytko, Nataliya L. ;

Makhson, Anatoly N. ;

Cortes, Javier ;

Lortholary, Alain ;

Bischoff, Joachim ;

Chan, Arlene ;

Delaloge, Suzette ;

Huang, Xin ;

Kern, Kenneth A. ;

Giorgetti, Carla .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :921-929

[6] Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial [J].

Carrato, Alfredo ;

Swieboda-Sadlej, Anna ;

Staszewska-Skurczynska, Marzanna ;

Lim, Robert ;

Roman, Laslo ;

Shparyk, Yaroslav ;

Bondarenko, Igor ;

Jonker, Derek J. ;

Sun, Yan ;

De la Cruz, Jhony A. ;

Williams, J. Andrew ;

Korytowsky, Beata ;

Christensen, James G. ;

Lin, Xun ;

Tursi, Jennifer M. ;

Lechuga, Maria J. ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) :1341-1347

[7] A Novel Preclinical Strategy for Identifying Cardiotoxic Kinase Inhibitors and Mechanisms of Cardiotoxicity [J].

Cheng, Hui ;

Kari, Gabor ;

Dicker, Adam P. ;

Rodeck, Ulrich ;

Koch, Walter J. ;

Force, Thomas .

CIRCULATION RESEARCH, 2011, 109 (12) :1401-U157

[8] Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab [J].

Choueiri, Toni K. ;

Mayer, Erica L. ;

Je, Youjin ;

Rosenberg, Jonathan E. ;

Nguyen, Paul L. ;

Azzi, Georges R. ;

Bellmunt, Joaquim ;

Burstein, Harold J. ;

Schutz, Fabio A. B. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :632-638

[9] Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer [J].

Crown, John P. ;

Dieras, Veronique ;

Staroslawska, Elzbieta ;

Yardley, Denise A. ;

Bachelot, Thomas ;

Davidson, Neville ;

Wildiers, Hans ;

Fasching, Peter A. ;

Capitain, Olivier ;

Ramos, Manuel ;

Greil, Richard ;

Cognetti, Francesco ;

Fountzilas, George ;

Blasinska-Morawiec, Maria ;

Liedtke, Cornelia ;

Kreienberg, Rolf ;

Miller, Wilson H., Jr. ;

Tassell, Vanessa ;

Huang, Xin ;

Paolini, Jolanda ;

Kern, Kenneth A. ;

Romieu, Gilles .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) :2870-+

[10] Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial [J].

de Boer, Richard H. ;

Arrieta, Oscar ;

Yang, Chih-Hsin ;

Gottfried, Maya ;

Chan, Valorie ;

Raats, Johann ;

de Marinis, Filippo ;

Abratt, Raymond P. ;

Wolf, Juergen ;

Blackhall, Fiona H. ;

Langmuir, Peter ;

Milenkova, Tsveta ;

Read, Jessica ;

Vansteenkiste, Johan F. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :1067-1074

← 1 2 3 4 →